NIH Issues Draft of Guidelines Governing Stem Cell Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

BETHESDA, Md-The National Institutes of Health has proposed a set of guidelines aimed at ensuring the ethical and legal conduct of any embryonic and fetal stem cell research that it funds.

BETHESDA, Md—The National Institutes of Health has proposed a set of guidelines aimed at ensuring the ethical and legal conduct of any embryonic and fetal stem cell research that it funds.

The guidelines sanction research on cell lines from fetal tissue, work that develops new cells lines from fetal tissue, and research on cell lines privately derived from human embryos.

The guidelines prohibit studies that would create or contribute to a human embryo, combine human stem cells with an animal embryo, or engage in reproductive cloning of a human. Also barred are studies in which stem cells are derived using somatic cell nuclear transfer into a human or animal egg, and those in which stem cells are derived from human embryos created for

Articles in this issue
Neoadjuvant Docetaxel Increases Response Rate in Large Breast Tumors
Faslodex, a Pure Antiestrogen, Shows Antitumor Activity
Consider Node Dissection, Adjuvant Therapy in Elderly Breast Cancer Patients
Tumor-Associated Proteases Predict Outcome in Node-Negative Patients
Herceptin Plus Vinorelbine a Promising Combination in Advanced Breast Cancer
Adjuvant Therapy Improves Relapse-Free Survival With Small, Node-Negative Tumors
Small Risk of Breast Cancer Death After Invasive Recurrence in DCIS Patients
Paclitaxel/Herceptin Effective in Metastatic Breast Cancer
Conservative Surgery Alone Not Sufficient to Prevent Recurrence
Surgical Margin Width Is a Reasonable Surrogate for Van Nuys Prognostic Index
Intensive Sequential Adjuvant Chemo for High-Risk Breast Cancer Patients
Anastrozole as Effective as Tamoxifen as First-Line Therapy of Advanced Breast Cancer
Sentinel Node Biopsy: Reasons for Failure
AT Superior to FAC in Metastatic Breast Cancer
New SERM Promising in Advanced Breast Cancer
Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content
According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?

Tim Cortese
November 29th 2025
Article

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Ariana Pelosci
November 26th 2025
Article

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.